Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 10;9(3):e91028.
doi: 10.1371/journal.pone.0091028. eCollection 2014.

Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India

Affiliations

Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India

Anita Shet et al. PLoS One. .

Abstract

Introduction: Adverse drug reactions related to antiretroviral therapy (ART) remain a challenge in resource-limited settings, often causing significant morbidity and impaired adherence leading to treatment failure. This 2-year prospective study aimed to describe patterns and predictors of adverse reactions to first-line ART and assess the impact of these events on treatment success.

Methods: Between 2010-2013, 321 ART-naïve eligible adults were enrolled at two clinics in southern India. ART regimens included zidovudine or stavudine plus lamivudine, plus nevirapine or efavirenz. Pill count adherence, immunological and virological monitoring, and laboratory-based adverse drug reactions were measured prospectively and analyzed.

Results: Among 321 patients in the study, 289 (90.0%) patients experienced at least 1 adverse reaction, and 85 (26.5%) experienced at least 1 severe reaction. The incidence rate was 52 and 15 per 100 person-years for all reactions and severe reactions respectively. The cumulative incidence of zidovudine-induced anemia was 37.1% over 2 years. At 12 and 24 months, the proportion of patients with optimal adherence, undetectable viral load and CD4 counts >350 cells/mm3 were similar between patients who experienced or did not experience severe adverse drug reactions.

Conclusions: Our results highlight the high frequency of ART-related adverse drug reactions among individuals initiating first-line ART in India, underscoring the importance of detailed counseling and monitoring for maintaining ART durability. Severe drug-induced anemia needs to be addressed urgently with alternative first-line agents, and close laboratory surveillance. High treatment efficacy despite decreased drug safety seen here may be because patients have limited treatment options. Our results support the use of currently recommended safer first-line ART regimens that minimize the risk of severe life-threatening toxicities and provide for a better quality of life.

Trial registration: ISRTCN Registry: ISRCTN79261738.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Recruitment flowchart and study outcomes.
1ART: Anti- Retroviral Treatment. 2ADR: Adverse Drug Reaction. 3Trial exclusion criteria: Participant in same household, no available phone network. 4NRTI: Nucleoside Reverse Transcription Inhibitor. 5NNRTI: Non-Nucleoside Reverse Transcription Inhibitor.

Similar articles

Cited by

References

    1. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT (2007) Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis 196 Suppl 3S449–456. - PubMed
    1. Max B, Sherer R (2000) Management of the adverse effects of antiretroviral therapy and medication adherence. Clinical Infectious Diseases 30 Suppl 2S96–116. - PubMed
    1. O’Brien ME, Clark RA, Besch CL, Myers L, Kissinger P (2003) Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 34: 407–414. - PubMed
    1. Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, et al. (2010) Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med 11: 104–113. - PubMed
    1. National AIDS Control Organisation Annual Report, 2012–2013. Department of AIDS Control. Ministry of Health and Family Welfare, New Delhi. Available: http://www.naco.gov.in/NACO/Quick_Links/Publication/Annual_Report/NACO_A.... Accessed 20 Jan 2014.

Publication types

Substances

Associated data